Kahn Jessica A, Belzer Marvin, Chi Xiaofei, Lee Jeannette, Gaur Aditya H, Mayer Kenneth, Martinez Jaime, Futterman Donna C, Stier Elizabeth A, Paul Mary E, Chiao Elizabeth Y, Reirden Daniel, Goldstone Steven E, Ortiz Martinez Ana P, Cachay Edward R, Barroso Luis F, Da Costa Maria, Wilson Craig M, Palefsky Joel M
Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Department of Pediatrics, University of Southern California, Los Angeles, CA, USA.
Papillomavirus Res. 2019 Jun;7:52-61. doi: 10.1016/j.pvr.2019.01.002. Epub 2019 Jan 15.
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11-6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03-5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. CLINICAL TRIAL NUMBER: NCT01209325.
1）确定肛门生殖器和口腔HPV的患病率；2）确定肛门、肛周、阴囊/阴茎和口腔部位HPV的一致性；3）描述与9价疫苗所针对的肛门生殖器HPV类型相关的因素。2012年至2015年期间，从参与一项疫苗试验的18至26岁男男性行为者中收集数据（N = 145）。对阴茎/阴囊、肛周、肛门和口腔样本进行了61种HPV类型的检测。采用逻辑回归来确定与9价疫苗中的类型相关的因素。参与者的平均年龄为23.0岁，55.2%为非裔美国人，26.2%为西班牙裔；93%有肛门HPV感染，40%有阴茎HPV感染，6%有口腔HPV感染。在有肛门生殖器感染的人群中，18%感染了HPV16。肛门生殖器和口腔部位之间的一致性较低。与9价疫苗型HPV独立相关的因素有：种族（非裔美国人与白人，OR = 2.67，95%CI = 1.11 - 6.42）、当前吸烟情况（是与否，OR = 2.37，95%CI = 1.03 - 5.48）以及近期接受肛交性伴侣的数量（2个及以上与0个，OR = 3.47，95%CI = 1.16 - 10.4）。大多数男男性行为者未感染HPV16或HPV18，这表明他们仍可能从HPV疫苗接种中获益，但肛门生殖器HPV非常常见，凸显了在男性开始性行为前进行疫苗接种的重要性。临床试验编号：NCT01209325。
